All In Biotech

Drug Trial Radar · NCT04333147

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,916 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,916

Actual

Start

May 12, 2020

Primary completion

Feb 24, 2023

Study completion Feb 24, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Apr 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RA is a chronic, systemic inflammatory autoimmune disease which requires treatment for a long time period, hence it is important to study the long-term safety and efficacy of the continuous treatment with GSK3196165 over several years. This is a Phase 3, multicenter, parallel group treatment and long-term extension study primarily to assess safety with efficacy assessment as a secondary objective. Adult participants with RA who have completed the treatment phase of a qualifying GSK3196165 clinical studies (Phase 3 studies contRAst 1 (201790: NCT03980483), contRAst 2 (201791: NCT03970837) and contRAst 3 (202018: NCT04134728) and who, in investigator's judgement will benefit from extended treatment with GSK3196165 will be included in this study (contRAst X \[209564: NCT04333147\]). Participants will continue to receive the same background conventional synthetic disease modifying anti-rheumatic drug(s) \[csDMARD(s)\] treatment as they received in their qualifying study. Eligible participants will be enrolled to receive weekly GSK3196165 90 milligrams (mg) or 150 mg by subcutaneous (SC) injection. The anticipated study duration is approximately 4 years which will enable participants to receive treatment with GSK3196165 until it is expected to become commercially available. Approximately 3000 participants from the qualifying studies will participate in this long-term extension study

Conditions

  • Arthritis, Rheumatoid

Interventions

  • Otilimab (GSK3196165)Biological

    GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.

  • csDMARD(s)Drug

    Stable dose of csDMARD(s) as standard of care (SoC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)Time frame: Up to approximately 145 Weeks
  2. Change From Baseline in Hematology Parameter of Platelet Count at Week 24Time frame: Baseline (Day 01) and Week 24
  3. Change From Baseline in Hematology Parameter of Platelet Count at Week 48Time frame: Baseline (Day 01) and Week 48
  4. Change From Baseline in Hematology Parameter of Platelet Count at Week 96Time frame: Baseline (Day 01) and Week 96
  5. Change From Baseline in Hematology Parameter of Platelet Count at Week 144Time frame: Baseline (Day 01) and Week 144
  6. Change From Baseline in Hematology Parameter of Hemoglobin at Week 24Time frame: Baseline (Day 01) and Week 24
  7. Change From Baseline in Hematology Parameter of Hemoglobin at Week 48Time frame: Baseline (Day 01) and Week 48
  8. Change From Baseline in Hematology Parameter of Hemoglobin at Week 96Time frame: Baseline (Day 01) and Week 96
  9. Change From Baseline in Hematology Parameter of Hemoglobin at Week 144Time frame: Baseline (Day 01) and Week 144
  10. Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 24Time frame: Baseline (Day 01) and Week 24
  11. Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 48Time frame: Baseline (Day 01) and Week 48
  12. Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 96Time frame: Baseline (Day 01) and Week 96
  13. Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 144Time frame: Baseline (Day 01) and Week 144
  14. Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 24Time frame: Baseline (Day 01) and Week 24
  15. Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 48Time frame: Baseline (Day 01) and Week 48
  16. Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 96Time frame: Baseline (Day 01) and Week 96
  17. Change From Baseline in Clinical Chemistry Parameter of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Gamma Glutamyl Transferase (GGT), Creatine Kinase (CPK) at Week 144Time frame: Baseline (Day 01) and Week 144
  18. Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 24Time frame: Baseline (Day 01) and Week 24
  19. Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 48Time frame: Baseline (Day 01) and Week 48
  20. Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 96Time frame: Baseline (Day 01) and Week 96
  21. Change From Baseline in Lipid Profile Parameter of Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein-Cholesterol (HDL), Triglycerides at Week 144Time frame: Baseline (Day 01) and Week 144
  22. Number of Participants With National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)>=Grade 3 Hematological/Clinical Chemistry AbnormalitiesTime frame: Up to approximately 145 Weeks
  23. Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 24Time frame: Baseline (Day 01) and Week 24
  24. Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 48Time frame: Baseline (Day 01) and Week 48
  25. Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 96Time frame: Baseline (Day 01) and Week 96
  26. Change From Baseline in Clinical Chemistry Parameter Total Bilirubin, Direct Bilirubin at Week 144Time frame: Baseline (Day 01) and Week 144

Locations

375 sites in 27 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Anniston, Alabama

  • GSK Investigational Site

    Flagstaff, Arizona

  • GSK Investigational Site

    Gilbert, Arizona

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Covina, California

  • GSK Investigational Site

    Poway, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Upland, California

  • GSK Investigational Site

    Van Nuys, California

  • GSK Investigational Site

    Whittier, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Fort Collins, Colorado

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Brandon, Florida

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Daytona Beach, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    Miami Lakes, Florida

  • GSK Investigational Site

    New Port Richey, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Palmetto Bay, Florida

  • GSK Investigational Site

    Tamarac, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Marietta, Georgia

  • GSK Investigational Site

    Idaho Falls, Idaho

  • GSK Investigational Site

    Skokie, Illinois

  • GSK Investigational Site

    Evansville, Indiana

  • GSK Investigational Site

    Wichita, Kansas

Showing 40 of 375 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.